Format

Send to

Choose Destination
BioDrugs. 2018 Oct;32(5):397-404. doi: 10.1007/s40259-018-0306-1.

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent.

Author information

1
Parker Institute, University of Copenhagen, Bispebjerg og Frederiksberg, Frederiksberg, Denmark.
2
Department of Internal Medicine, Rheumatology, Lund University, Lund, Sweden.
3
Department of Internal Medicine, Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany.
4
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
5
Department of Dermatology, Venereology and Allergy, Charité Universitätsmedizin, Berlin, Germany.
6
Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
7
Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
8
Department of Rheumatology, Sint Maartenskliniek and Radboud University Medical Centre, Nijmegen, The Netherlands.
9
Institute of Rheumatology, Prague, Czech Republic.
10
Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands. a.vulto@gmail.com.
11
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. a.vulto@gmail.com.

Abstract

The nocebo effect is defined as the incitement or the worsening of symptoms induced by any negative attitude from non-pharmacological therapeutic intervention, sham, or active therapies. When a patient anticipates a negative effect associated with an intervention, medication or change in medication, they may then experience either an increase in this effect or experience it de novo. Although less is known about the nocebo effect compared with the placebo effect, widespread interest in the nocebo effect observed with statin therapy and a literature review highlighting the nocebo effect across at least ten different disease areas strongly suggests this is a common phenomenon. This effect has also recently been shown to play a role when introducing a medication or changing an established medication, for example, when switching patients from a reference biologic to a biosimilar. Given the important role biosimilars play in providing cost-effective alternatives to reference biologics, increasing physician treatment options and patient access to effective biologic treatment, it is important that we understand this phenomenon and aim to reduce this effect when possible. In this paper, we propose three key strategies to help mitigate the nocebo effect in clinical practice when switching patients from reference biologic to biosimilar: positive framing, increasing patient and healthcare professionals' understanding of biosimilars and utilising a managed switching programme.

PMID:
30269270
PMCID:
PMC6182448
DOI:
10.1007/s40259-018-0306-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center